• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.

    5/13/25 8:50:01 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care
    Get the next $EMBC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Embecta Corp.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    29082K105

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    29082K105


    1Names of Reporting Persons

    Deerfield Mgmt, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,720,535.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,720,535.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,720,535.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.66 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Comprised of shares of common stock held by Deerfield Partners, L.P., of which Deerfield Mgmt, L.P. is the general partner.


    SCHEDULE 13G

    CUSIP No.
    29082K105


    1Names of Reporting Persons

    Deerfield Management Company, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,720,535.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,720,535.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,720,535.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.66 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Comprised of shares of common stock held by Deerfield Partners, L.P., of which Deerfield Management Company, L.P. is the investment advisor.


    SCHEDULE 13G

    CUSIP No.
    29082K105


    1Names of Reporting Persons

    Deerfield Partners, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,720,535.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,720,535.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,720,535.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.66 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    29082K105


    1Names of Reporting Persons

    James E. Flynn
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,720,535.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,720,535.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,720,535.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.66 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Comprised of shares of common stock held by Deerfield Partners, L.P.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Embecta Corp.
    (b)Address of issuer's principal executive offices:

    300 Kimball Drive, Suite 300, Parsippany, NJ 07054
    Item 2. 
    (a)Name of person filing:

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.P.
    (b)Address or principal business office or, if none, residence:

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.P., 345 Park Avenue South, 12th Floor, New York, NY 10010
    (c)Citizenship:

    Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P. - Delaware limited partnerships; James E. Flynn - United States citizen
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    29082K105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Deerfield Mgmt, L.P. - 2,720,535 shares Deerfield Management Company, L.P. - 2,720,535 shares Deerfield Partners, L.P. - 2,720,535 shares James E. Flynn - 2,720,535 shares
    (b)Percent of class:

    Deerfield Mgmt, L.P. - 4.66% Deerfield Management Company, L.P. - 4.66% Deerfield Partners, L.P. - 4.66% James E. Flynn - 4.66%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    All Reporting Persons - 0

     (ii) Shared power to vote or to direct the vote:

    Deerfield Mgmt, L.P. - 2,720,535 Deerfield Management Company, L.P. - 2,720,535 Deerfield Partners, L.P. - 2,720,535 James E. Flynn - 2,720,535

     (iii) Sole power to dispose or to direct the disposition of:

    All Reporting Persons - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Deerfield Mgmt, L.P. - 2,720,535 Deerfield Management Company, L.P. - 2,720,535 Deerfield Partners, L.P. - 2,720,535 James E. Flynn - 2,720,535

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit B
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Deerfield Mgmt, L.P.
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-In-Fact
    Date:05/13/2025
     
    Deerfield Management Company, L.P.
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-In-Fact
    Date:05/13/2025
     
    Deerfield Partners, L.P.
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-In-Fact
    Date:05/13/2025
     
    James E. Flynn
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-In-Fact
    Date:05/13/2025
    Exhibit Information

    Exhibit A. Joint Filing Agreement. Exhibit B. Item 8 Statement. Exhibit C. Power of Attorney (1). (1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.

    Get the next $EMBC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EMBC

    DatePrice TargetRatingAnalyst
    4/10/2025$15.00Neutral
    Mizuho
    12/2/2024$13.00 → $20.00Underweight → Equal-Weight
    Morgan Stanley
    11/27/2024$26.00Neutral → Buy
    BTIG Research
    10/20/2023Peer Perform
    Wolfe Research
    1/6/2023$28.00Equal-Weight → Underweight
    Morgan Stanley
    9/8/2022Neutral
    BTIG Research
    8/1/2022$33.00Equal-Weight
    Morgan Stanley
    6/21/2022$25.00Underperform
    BofA Securities
    More analyst ratings

    $EMBC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.

    SCHEDULE 13G/A - Embecta Corp. (0001872789) (Subject)

    8/14/25 9:01:17 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Embecta Corp.

    10-Q - Embecta Corp. (0001872789) (Filer)

    8/8/25 11:44:34 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Embecta Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Embecta Corp. (0001872789) (Filer)

    8/8/25 7:01:25 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Human Resources Officer Casner Jean covered exercise/tax liability with 916 shares, decreasing direct ownership by 2% to 48,799 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    8/11/25 5:06:47 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Director Melcher David F bought $105,995 worth of shares (10,000 units at $10.60), increasing direct ownership by 13% to 86,681 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    5/23/25 4:35:56 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    SVP and CFO Elguicze Jacob covered exercise/tax liability with 4,948 shares, decreasing direct ownership by 3% to 168,599 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    4/8/25 4:25:00 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on Embecta Corp. with a new price target

    Mizuho initiated coverage of Embecta Corp. with a rating of Neutral and set a new price target of $15.00

    4/10/25 12:41:09 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Embecta Corp. upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Embecta Corp. from Underweight to Equal-Weight and set a new price target of $20.00 from $13.00 previously

    12/2/24 6:56:10 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Embecta Corp. upgraded by BTIG Research with a new price target

    BTIG Research upgraded Embecta Corp. from Neutral to Buy and set a new price target of $26.00

    11/27/24 7:22:14 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Melcher David F bought $105,995 worth of shares (10,000 units at $10.60), increasing direct ownership by 13% to 86,681 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    5/23/25 4:35:56 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Director Melcher David F bought $177,646 worth of shares (13,000 units at $13.67), increasing direct ownership by 20% to 76,681 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    2/25/25 4:26:16 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Melcher David F bought $32,500 worth of shares (2,000 units at $16.25), increasing direct ownership by 5% to 45,080 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    2/12/24 7:08:59 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Embecta Corp. Reports Third Quarter Fiscal 2025 Financial Results

    PARSIPPANY, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2025. "Q3 was a strong quarter for embecta, reflecting solid commercial execution, aided in part by the timing of customer orders. Despite an increasingly complex and dynamic geopolitical environment, given the year-to-date performance and our outlook for the remainder of the year, we are tightening and raising our fiscal 2025 outlook for key financial metrics," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer of embecta. Mr. Kurdi

    8/8/25 6:30:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta Announces Quarterly Cash Dividend

    PARSIPPANY, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on September 15, 2025 to stockholders of record at the close of business on August 29, 2025. About embecta embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow

    8/8/25 6:00:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta to Report Fiscal Third Quarter 2025 Financial Results

    PARSIPPANY, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal third quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, August 8, 2025. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00

    7/24/25 5:00:00 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Leadership Updates

    Live Leadership Updates

    View All

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

    3/11/25 7:00:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors

    WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (NASDAQ:EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world.  "We are pleased to welcome Dev to the ZB Board," said Chris Begley, Chairman of the

    6/20/24 7:30:00 AM ET
    $EMBC
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    $EMBC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Embecta Corp.

    SC 13G/A - Embecta Corp. (0001872789) (Subject)

    11/8/24 10:57:43 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Embecta Corp.

    SC 13G/A - Embecta Corp. (0001872789) (Subject)

    11/7/24 4:21:15 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Embecta Corp.

    SC 13G - Embecta Corp. (0001872789) (Subject)

    10/25/24 5:45:30 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Financials

    Live finance-specific insights

    View All

    Embecta Corp. Reports Third Quarter Fiscal 2025 Financial Results

    PARSIPPANY, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2025. "Q3 was a strong quarter for embecta, reflecting solid commercial execution, aided in part by the timing of customer orders. Despite an increasingly complex and dynamic geopolitical environment, given the year-to-date performance and our outlook for the remainder of the year, we are tightening and raising our fiscal 2025 outlook for key financial metrics," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer of embecta. Mr. Kurdi

    8/8/25 6:30:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta Announces Quarterly Cash Dividend

    PARSIPPANY, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on September 15, 2025 to stockholders of record at the close of business on August 29, 2025. About embecta embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow

    8/8/25 6:00:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta to Report Fiscal Third Quarter 2025 Financial Results

    PARSIPPANY, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal third quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, August 8, 2025. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00

    7/24/25 5:00:00 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care